Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study).
X-ray computed
follow-up studies
melanoma
positron emission tomography computed tomography
prospective studies
quality of life
randomized controlled trial
tomography
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Feb 2022
18 Feb 2022
Historique:
received:
19
01
2022
revised:
15
02
2022
accepted:
16
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
The benefit of imaging in the follow-up setting for high-risk melanoma patients is uncertain, and even less is known about the impact of intensive follow-up on the patient´s quality of life. In 2017, a Swedish prospective randomized multicenter study started, in which high-risk melanoma patients are randomly assigned 1:1 to follow-up by physical examinations +/- whole-body imaging. The first-year examinations are scheduled at 0, 6 and 12 months. The aim of this study was to investigate whether the patients´ health-related quality of life (HRQoL) and levels of anxiety and depression were affected at 1 year by imaging. Anxiety/depression and HRQoL were assessed at 0 and 12 months by the questionnaires Hospital Anxiety and Depression (HAD) scale and EORTC QLQ-C30 version 3. Expected baseline QLQ-C30 values for the patients were calculated using data from the general population. In total, 204 patients were analyzed. Mean differences in subscale scores at 1 year were not statistically significant either for HRQoL or for anxiety/depression. Baseline HRQoL did not differ from expected values in the general Swedish population. In conclusion, the patients in general coped well with the situation, and adding whole-body imaging to physical examinations did not affect the melanoma patients' HRQoL or levels of anxiety or depression.
Identifiants
pubmed: 35205786
pii: cancers14041040
doi: 10.3390/cancers14041040
pmc: PMC8869964
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond
ID : Not applicable
Organisme : Lion´s Cancer fund
ID : Not applicable
Références
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
J Am Acad Dermatol. 2016 Sep;75(3):516-524
pubmed: 27183845
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Ann Oncol. 2018 Jul 1;29(7):1569-1574
pubmed: 29659679
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
BMC Cancer. 2020 Dec 7;20(1):1197
pubmed: 33287744
Eur J Surg Oncol. 2021 Dec;47(12):3020-3027
pubmed: 34120809
J Clin Oncol. 2018 Mar 1;36(7):667-673
pubmed: 28991513
JAMA. 1994 May 25;271(20):1587-92
pubmed: 8182811
J Surg Res. 2017 Jun 15;214:32-37
pubmed: 28624057
Ann Surg Oncol. 2019 Jun;26(6):1860-1868
pubmed: 30911946
Acta Oncol. 2000;39(4):477-84
pubmed: 11041109
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Plast Reconstr Surg. 2016 Aug;138(2):330e-340e
pubmed: 27465194
Eur J Cancer. 2012 Sep;48(13):2012-9
pubmed: 22196968